Nebulized formoterol effect on bronchodilation and satisfaction in COPD patients compared to QID ipratropium/albuterol MDI

References

• Buist S. COPD: A common disease that is preventable and treatable. Prim Care Resp J 2006;15:7-9
   PubMedGoogle Scholar
• Punturieri A, Croxton TL, Weinmann MD, et al. The changing face of COPD. Am Family Physician 2007;75:315-16
   PubMed Web of Science ®Google Scholar
• Hanania NA. Optimizing maintenance therapy for chronic obstructive pulmonary disease: strategies for improving patient-centered outcomes. Clin Ther 2007;29:2121-33
   PubMed Web of Science ®Google Scholar
• Celli BR, Thomas NE, Anderson JA, et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease. Results from the TORCH study. Am J Respir Crit Care Med 2008;178:332-8
   PubMed Web of Science ®Google Scholar
• Global Initiative for chronic obstructive lung disease (GOLD).. Report of the GOLD workshop, global strategy for diagnosis, management and prevention of COPD. 2007 update. Available at: http://www.goldcopd.com [Last accessed 27 October 2008]
   Google Scholar
• Appleton S, Poole P, Smith B, et al.Long-acting beta2-agonists for poorly reversible chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews (online), 2006;3: CD001104
   Google Scholar
• Dahl R, Greefhorst LAPM, Nowak D, et al. Inhaled formoterol; dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;164:778-84
   PubMed Web of Science ®Google Scholar
• Aalbers R, Ayres J, Backer V, et al. Formoterol in patients with chronic obstructive pulmonary disease: a randomized, controlled, 3-month trial. Eur Respir J 2002;19:936-43
   PubMed Web of Science ®Google Scholar
• Rossi A, Kristufek P, Levine B, et al. Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD. Chest 2002;121:1058-69
   PubMed Web of Science ®Google Scholar
• Berger WE, Nadel JA. Efficacy and safety of formoterol for the treatment of chronic obstructive pulmonary disease. Resp Med 2008;102:173-88
   PubMed Web of Science ®Google Scholar
• Gross NJ, Nelson HS, Lapidus RJ, et al. Efficacy and safety of formoterol fumarate delivered by nebulization to COPD patients. Resp Med 2008;102:189-97
   PubMed Web of Science ®Google Scholar
• Combivent Inhalation Aerosol Study Group. In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. Chest 1994;105:1411-19
   PubMed Web of Science ®Google Scholar
• Dorinsky PM, Reisner C, Ferguson GT, et al. The combination of ipratropium and albuterol optimizes pulmonary function reversibility testing in patients with COPD. Chest 1999;115:966-71
   PubMed Web of Science ®Google Scholar
• Campbell S. For COPD a combination of ipratropium bromide and albuterol sulfate is more effective than albuterol base. Arch Intern Med 1999;159:156-60
   PubMed Web of Science ®Google Scholar
• Gross N, Tashkin D, Miller R, et al. Inhalation by nebulization of albuterol-ipratropium combination (Dey combination) is superior to either agent alone in the treatment of chronic obstructive pulmonary disease. Respiration 1998;65:354-62
   PubMed Web of Science ®Google Scholar
• Make B, Hanania NA, ZuWallack R, et al. The efficacy and safety of inhaled fluticasone propionate/salmeterol and ipratropium/albuterol for the treatment of chronic obstructive pulmonary disease: an eight-week, multicenter, randomized, double-blind, double-dummy, parallel-group study. Clin Ther 2005;27:531-42
   PubMed Web of Science ®Google Scholar
• Donohue JF, Kalberg C, Emmett A, et al. A short-term comparison of fluticasone propionate/salmeterol with ipratropium bromide/albuterol for the treatment of COPD. Treat Respir Med 2004;3:173-81
   PubMedGoogle Scholar
• D’Urzo AD, De Salvo MC, Ramirez-Rivera A, et al. In patients with COPD, treatment with a combination of formoterol and ipratropium is more effective than a combination of salbutamol and ipratropium: a 3-week, randomized, double-blind, within-patient, multicenter study. Chest 2001;119:1347-56
   PubMed Web of Science ®Google Scholar
• Mahler DA, Weinberg DH, Wells CK, et al. The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest 1984;85:751-8
   Google Scholar
• Van Noord JA, de Munck DRAJ, Bantje TA, et al. Long-term treatment of chronic obstructive pulmonary disease with salmeterol and the additive effect of ipratropium. Eur Respir J 2000;15:878-85
   PubMed Web of Science ®Google Scholar
• Barta SK, Crawford A, Roberts CM. Survey of patients’ views of domiciliary nebuliser treatment for chronic lung disease. Respir Med 2002;96:375-81
   PubMed Web of Science ®Google Scholar
• O’Driscoll BR, Kay EA, Taylor RJ, et al. A long-term prospective assessment of home nebuliser treatment. Respir Med 1992;86:317-25
   PubMed Web of Science ®Google Scholar
• Dolovich MB, Ahrens RC, Hess DR, et al. Device selection and outcomes of aerosol therapy: evidence-based guidelines. Chest 2005;127:335-71
   PubMed Web of Science ®Google Scholar
• O’Driscoll BR, Bernstein A. A long-term study of symptoms, spirometry and survival amongst home nebuliser users. Respir Med 1996;90:561-6
   PubMed Web of Science ®Google Scholar
• van Beerendonk I, Mesters I, Mudde AN, et al. Assessment of the inhalation technique in outpatients with asthma or chronic obstructive pulmonary disease using a metered-dose inhaler or dry powder device. J Asthma 1998;35:273-9
   PubMed Web of Science ®Google Scholar
• O’Donohue WJ. Guidelines for the use of nebulizers in the home and at domiciliary sites. Report of a consensus conference. National Association for Medical Direction of Respiratory Care (NAMDRC) Consensus Group. Chest 1996;109:814-20
   Google Scholar
• Melani AS, Zanchetta D, Barbato N, et al. Inhalation technique and variables associated with misuse of conventional metered-dose inhalers and newer dry powder inhalers in experienced adults. Ann Allergy Asthma Immunol 2004;93:439-46
   PubMed Web of Science ®Google Scholar
• Jarvis S, Ind PW, Shiner RJ. Inhaled therapy in elderly COPD patients; time for re-evaluation? Age Aging 2007;36:213-18
   PubMed Web of Science ®Google Scholar